直接抗病毒方案在HIV/HCV合并感染患者中的疗效与安全性——法国ANRS CO13 HEPAVIH队列研究
在法国全国性观察性队列ANRS CO13 HEPAVIH中,323例HIV/HCV合并感染患者接受全口服直接抗病毒方案治疗,总体SVR12为93.5%(95%CI 90.2-95.9),肝硬化与非肝硬化患者分别为93.3%与93.8%。调整分析显示SVR12与HIV RNA载量、cART方案、肝硬化、既往抗HCV治疗、抗HCV疗程或利巴韦林使用无关。方案耐受性良好,最常见不良事件为疲劳和消化系统疾病。
要点
- HIV/HCV合并感染者全口服DAA方案总体SVR12为93.5%(95%CI 90.2-95.9)。
- 肝硬化患者SVR12为93.3%(95%CI 88.8-96.4),非肝硬化患者为93.8%(95%CI 88.1-97.3)。
- 调整分析中SVR12与cART方案、肝硬化、既往抗HCV治疗等无关。
核心结论
- 全口服DAA方案在HIV/HCV合并感染患者中耐受性良好,并取得较高的SVR12率。
研究设计与样本
- 法国全国性观察性队列ANRS CO13 HEPAVIH,纳入323例在2015年5月1日前开始12周方案或在2015年2月1日前开始24周方案的全口服DAA方案HIV/HCV合并感染患者。
- 治疗成功定义为治疗结束后12周HCV-RNA检测不到(SVR12),采用精确logistic回归分析SVR12相关因素。
主要发现
- 总体SVR12为93.5%(95%CI 90.2-95.9),肝硬化患者为93.3%(95%CI 88.8-96.4),非肝硬化患者为93.8%(95%CI 88.1-97.3)。
- 以蛋白酶抑制剂(PI)为基础、非核苷类逆转录酶抑制剂(NNRTI)为基础和整合酶抑制剂(II)为基础cART的患者SVR12分别为93.1%(95%CI 84.5-97.7)、91.8%(95%CI 80.4-97.7)和95.8%(95%CI 90.5-98.6)。
- 调整分析中,SVR12与HIV RNA载量、cART方案、肝硬化、既往抗HCV治疗、抗HCV疗程或利巴韦林使用无关。
- 最常见的不良反应为疲劳和消化系统疾病。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: There is little data available on the use of new oral direct-acting antiviral (DAA) regimens to treat human immunodeficiency virus and hepatitis C virus (HIV/HCV) co-infected patients in real-life settings. Here, the efficacy and safety of all-oral DAA-based regimens in HIV/HCV-co-infected patients enrolled in the French nationwide ANRS CO13 HEPAVIH observational cohort are reported. METHODS: HIV/HCV-co-infected patients enrolled in the ANRS CO13 HEPAVIH observational cohort were included if they began an all-oral DAA-based regimen before 1st May 2015 (12-week regimens) or 1st February 2015 (24-week regimens). Treatment success (SVR12) was defined by undetectable HCV-RNA 12weeks after treatment cessation. Exact logistic regression analysis was used to identify factors associated with SVR12. RESULTS: A total of 323 patients (74% men) with a median age of 53years were included, 99% of whom were on combination antiretroviral therapy (cART). HIV RNA load was <50 copies/ml in 88% of patients; median CD4 cell count was 540/mm3; 60% of patients were cirrhotic; 68% had previously received unsuccessful anti-HCV treatment. cART was protease inhibitor (PI)-based in 23%, non-nucleoside reverse transcriptase inhibitor (NNRTI)-based in 15%, and integrase inhibitor (II)-based in 38%, while 24% of patients received other regimens. The SVR12 rate was 93.5% overall (95% confidence interval [CI]: 90.2-95.9), 93.3% (88.8-96.4) in patients with cirrhosis and 93.8% (88.1-97.3) in patients without cirrhosis. The SVR12 rates were 93.1% (84.5-97.7), 91.8% (80.4-97.7) and 95.8% (90.5-98.6) respectively, in patients receiving PI-based, NNRTI-based and II-based cART. In adjusted analysis, SVR12 was not associated with HIV RNA load, the cART regimen, cirrhosis, prior anti-HCV treatment, the duration of anti-HCV therapy, or ribavirin use. The most common adverse effects were fatigue and digestive disorders. CONCLUSIONS: New all-oral DAA regimens were well-tolerated and yielded high SVR12 rates in HIV/HCV-co-infected patients. LAY SUMMARY: We evaluated efficacy and safety of all-oral DAA regimens in a large French nationwide observational cohort study of HIV/HCV co-infected patients. Sustained virological response 12weeks after treatment cessation was 93.5% overall. The all-oral DAA regimens were well-tolerated and most common adverse effects were fatigue and digestive disorders.
引用
- Piroth L, Wittkop L, Lacombe K, et al. Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients - French ANRS CO13 HEPAVIH cohort. J Hepatol. 2017. PMID: 28235612. doi:10.1016/j.jhep.2017.02.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。